At a glance
- Originator Nonindustrial source; Xenova Group
- Class Antineoplastics
- Mechanism of Action Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 02 Aug 2002 Discontinued - Preclinical for Cancer in England (unspecified route)
- 19 Jul 1999 New profile
- 19 Jul 1999 Preclinical development for Cancer in England (Unknown route)